Founded in 1886 in New burnswick New Jerssey, USA J&J spread its roots in India in 1947 In 1948 started

marketing of Johnson's baby powder which was manufactured by local drug co. British Drug House Co. got registered in 1957 and started production at Mulund in Mumbai in 1959. In 1960s co. started growing & establish its first manufacturing plant in Mumbai.

In over 50 years co. has gained immense reputation & continuous delivering high quality products.

PRODUCTS
Categories of healthcare segment: Consumer Medical devices & diagnostics Janssen Ortho clinical diagnostics Vision care Consumer: J&J touches a billion of lives through 5 consumer business segment: Baby Care Womens Health Beauty OTC Oral & Wound Care

Other Product category Medical Devices and Diagnostics :

ASP Ethic Cardiovascular Care De Puy Ethicon Endo Surgery J&J Hospital Supplies Life scan

JANSSEN: Janssen, a division of Johnson & Johnson Limited is dedicated to addressing and solving the unmet medical needs in Primary Care and Specialty Care ORTHO CLINICAL DIAGNOSTICS: Ortho Clinical Diagnostics serves the transfusion medicine community and laboratories around the world. J&J are the leading provider of total solutions for screening, diagnosing, monitoring and confirming diseases before they put lives at risk. The Company maintains a leadership position in two major market segments: Transfusion Medicine Clinical laboratories VISION CARE: Johnson & Johnson Vision Care is a company committed to transforming the world's vision.

Generally J&J deals in products category but it deal into these services category too
PROFESSIONAL EDUCATION:

J&J is committed towards providing profession education to the society for which it started two institute who deals in professional education Ethicon Institute Of Surgical Education (EISE) DePuy Institute

VISION
The fundamental objective of Johnson & Johnson is to provide scientifically sound, high quality products and services to help heal, cure disease and improve the quality of life

MISSION We are responsible to the communities in which we live and work and to the world community as well.

Major Competitors
Ranbaxy laboratories ltd. Pfizer ltd. GSK plc. Novartis AG Reckid & Mainkizer P&G

Market share
GOALS OF J&J:

Johnson & Johnson will continue to bring meaningful innovations to people around the world so they can live better and healthier lives. We are deeply committed and dedicated to the people who use our products, our employees, the communities in which we live and work, and you, our shareholders.
These are the goals which Johnson & Johnson follows. To fulfill its goals J&J do these activities

Nanhi kalhi Humana people to people India Prerna Tulips school SOS children Villages SOS Nurses program

Market Capture
Delivering operational sales growth in its 28th consecutive year Our sales is $65 billion We maintained AAA credit rating this year also Dividend per share $2.290 Jhonson & Jhonson market capitalization is $57080 million.

SWOT Analysis Johnson & Johnson Strengths A Substantial Marketing Arsenal Johnson & Johnson can call upon a network of subsidiaries armed with significant sales and marketing prowess, as well as expertise in a number of therapy areas. The company possesses a global sales force which serves to attract joint venture possibilities. Strategic Acquisitions Johnson & Johnson has maintained a stable financial position by utilizing cash reserves to finance timely corporate acquisitions. Its Triple A Credit Rating represents a company able to take advantage of opportunities that arise without being limited by burdensome levels of debt. Product Diversification The Johnson & Johnson pharmaceutical portfolio, and ts large Medical Devices & Diagnostics (M,D &D) and Consumer Health divisions serves to reduce dependence upon any one area. The company plans to continue this broadening through 2008-14. This diversification allows a wider range of choice when pursuing opportunities with the greatest growth prospects. Positive Revenue Growth Projections The potential of an impressive number of new product launches and the promise of achieving forecast sales is said to bode well for Johnson & Johnson, helping it weather the recent decline in prescription pharmaceuticals and projecting a turn-around through 2010. An increase at 1.8% CAGR across 200814 is believed to be achievable.

Weaknesses Dependence on the Success of Launch Products Many new launch products are vulnerable to the uncertainty of regulatory review and ultimate market benefits may vary substantially from forecast, therefore, a reliance upon launch products potentially represents a threat to Johnson & Johnsons outlook. Reliance on Small Molecule Drugs Compared to biologics, small molecules are notably more impacted by generic competition. As such, although the Johnson & Johnson is engaged in producing new small molecule products, when coming off-patent, declines are still forecast. This is particularly the case in the US, where generic erosion rates are most aggressive. Johnson & Johnsons small molecule drug sales declined in 2008 and are forecast to fall further into 2012. Teses issues reflect concerns expressed across the pharmaceutical industrythe necessity of finding replacements for billion dollar products as they mature represents an daunting task.

Opportunities Wide Range of Potential Cross-selling Opportunities Johnson & Johnson is in a position to strategically develop a myriad of cross selling opportunities. Using the disease life cycle as a base the company could exploit its product line in CV, oncology, diabetes and I&I therapy to formulate linkages between patents and care-giving resulting in greater efficiency. Maximizing its balance between Pharmaceuticals, Diagnostics, and Medical Devices could result in increased revenues. Potential to Exploit Biologics Market The addition of further biologics to its portfolio can serve as a buffer as mall molecule patents expiries. J&J is experienced in the development and commercialization of biologics including the therapeutic proteins Procrit and Natrecor, and monoclonal antibodies Remicade, ReoPro, Simponi and Stelara. This represents an opportunity to gain key IP, product rights or strengthen discovery capabilities. In July of 2009 Johnson & Johnson was selected by Elan to form a joint venture for the development and commercialization of these products. In addition, J&J acquired an 18.4% equity stake in the company.

THREATS

Dependence on the Success of Launch Products Many new launch products are vulnerable to the uncertainty of regulatory review and ultimate market benefits may vary substantially from forecast, therefore, a reliance upon launch products potentially represents a threat to Johnson & Johnsons outlook. Negative Impact of Recent Product Recalls Johnson and Johnson has the misfortune of having to recall of more than 40 medicines recently. FDA inspectors required the company to recall the children's medications after discovering the company had not looked into dozens of consumer complaints about "black or dark specks" in Tylenol and other products. The company stands to take a hit to its sterling reputation as congressional lawmakers are blasting the company's competence and integrity. Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Company Competing Values

Competing Values is about understanding how to appreciate conflicting values and integrate them successfully so that the organization is open to collaboration and growth.

COMPETING VALUES
Focus: Goals Situation: Shareholder demands are the primary driver, aggressive competition,
markets change from mergers and acquisitions, investors demand quick results

Purposes: Profits and speed Practices: Managing performance through objectives, investing for increasing rates of
return, quickly starting and killing initiatives, quickly confronting problems

People: Goal oriented, assertive, driven, accountable, decisive, competitive Environment: High pressure, fast moving, quantifiable results, pay for performance Measures: Gross Profit, time to market, return on investment, operating income